Roche adjusts Avastin franchise defense plans as PhII successor fails a key study
Vanucizumab was supposed to be Roche’s answer to the biosimilars of Avastin that are now steadily winding their way through the clinic on a short path to regulators. But in a Phase II head-to-head between new and old, the successor drug failed to distinguish itself. And now Roche is dropping its development as a monotherapy while pushing on with combos and high hopes for its marquee checkpoint drug Tecentriq.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.